Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2023 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2787 64Cu-DOTATATE PET/CT Imaging of Patients with Neuroendocrine Neoplasms Can Be Performed between 1 and 3 Hours after Radiotracer Injection: Comparison of Lesion Detection Ability and Contrast

Introduction: PET/CT imaging of patients with neuroendocrine neoplasms (NEN) 1 hour (h) post injection (pi) of 64Cu-DOTATATE has shown superiority in lesion detection when compared to other clinically available somatostatin receptor imaging (SRI) modalities.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Loft M, Johannesen H, Carlsen E, Johnbeck C, Binderup T,

Keywords: 64Cu-DOTATATE, Neuroendocrine Neoplasms, PET Imaging, Somatostatin Receptor Imaging,

#2717 64Cu-DOTATATE PET/CT Predicts Progression-Free Survival in Patients with Neuroendocrine Neoplasms

Introduction: The degree of overexpression of somatostatin receptors in patients with neuroendocrine neoplasms (NEN) may reflect tumor differentiation and thus be associated with prognosis. Non-invasive quantification of receptor density is possible by somatostatin receptor imaging (SRI) using positron emission tomography (PET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carlsen E

Authors: Carlsen E, Johnbeck C, Binderup T, Loft M, Pfeifer A,

Keywords: 64Cu-dotatate, neuroendocrine neoplasm, progression-free survival, overall survival,

#1789 FDG-PET is Superior to WHO Grading in Predicting Overall Survival of Patients with Neuroendocrine Tumors: A Prospective Study of 172 Patients

Introduction: Accurate grading of patients with neuroendocrine tumors (NETs) is essential for risk stratification and optimal choice of therapy. Currently, WHO grading is based on histo-pathologically assessed degree of tumor proliferation.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kjaer A

Authors: Binderup T, Johnbeck C, Loft A, Berthelsen A, Federspiel B,

Keywords: PET, PET/CT, imaging, survival,

#1370 68Ga-DOTATOC PET and Gene Expression Profile in Patients with Neuroendocrine Carcinomas

Introduction: Somatostatin receptor expression on both protein and gene expression levels were compared with in vivo 68Ga-DOTATOC PET/CT in patients with neuroendocrine carcinomas (NEC).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Olsen I

Authors: Olsen I, Langer S, Federspiel B, Oxbøl J, Loft A,

Keywords: neuroendocrine carcinoma, gene expression, 68Ga-DOTATOC, IHC, SSTR2,

#472 Detection of Liver Metastases and Prognostic Value of Functional and Anatomical Imaging in Patients with Neuroendocrine Tumors

Introduction: Liver metastases (LM) are frequent in patients with neuroendocrine tumors (NETs) and are associated with decreased overall survival (OS). Several treatment options are available depending on degree, localization, size and number of LM. For optimal choice of treatment and correct staging, accurate imaging modalities are crucial.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Knigge U, Binderup T, Federspiel B, Palnæs Hansen C, Loft A,

Keywords: ,

Abstract Submissions in 2023

Abstract submissions for 2024 will open in September 2023!


The 21st Annual ENETS Conference in 2024 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.


Participants of the ENETS Conferences in 2023 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.